Sarcoma Immunotherapy: Past Approaches and Future Directions
Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25–50% of patients treated with initial curative intent will develop metastatic disease. In the metastatic setting, chemotherapy rarely leads to complete and durable res...
Main Authors: | S. P. D'Angelo, W. D. Tap, G. K. Schwartz, R. D. Carvajal |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1155/2014/391967 |
Similar Items
-
Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
by: S. P. D’Angelo, et al.
Published: (2015-01-01) -
Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions
by: Lisheng Ge, et al.
Published: (2010-01-01) -
Is immunotherapy in the future of therapeutic management of sarcomas?
by: Ottavia Clemente, et al.
Published: (2021-04-01) -
Past, Current, and Future of Immunotherapies for Prostate Cancer
by: Adeline N. Boettcher, et al.
Published: (2019-09-01) -
Sarcoma Immunotherapy
by: R. Lor Randall, et al.
Published: (2011-11-01)